Estimating individual lifetime benefit and bleeding risk with NOAC addition to asprin in stable CVD - PACE-CME

Estimating individual lifetime benefit and bleeding risk with NOAC addition to asprin in stable CVD

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Biochemical urine test to measure medical adherence in hypertension
Biochemical urine test to measure medical adherence in hypertension
ESC 2019
Biochemical urine test to measure medical adherence in hypertension
Betablocker use associated with reduced mortality in HFrEF patients >80 years
Betablocker use associated with reduced mortality in HFrEF patients >80 years
ESC 2019
Betablocker use associated with reduced mortality in HFrEF patients >80 years
- Gianluigi Savarese, MD
Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM
Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM
ESC 2019
Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM
- Jan Westerink, MD, PhD
Sex-related differences in ACS patients
Sex-related differences in ACS patients
ESC 2019
Sex-related differences in ACS patients
- Sanne Peters, PhD